European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA
Cinnamon Girl said
Jan 19, 2015
NORTH CHICAGO, Ill., Jan. 16, 2015 -- AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX(ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(dasabuvir tablets).
The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
"The approval of AbbVie's hepatitis C treatment in the European Union, following the recent approvals in the U.S. and Canada, offers patients across Europe a new and effective treatment to cure this serious disease," said Richard Gonzalez, chairman of the board and chief executive officer, AbbVie. "We are committed to working with local governments and healthcare systems to support broad access to VIEKIRAX + EXVIERA."
NORTH CHICAGO, Ill., Jan. 16, 2015 -- AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets).
The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.
Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
"The approval of AbbVie's hepatitis C treatment in the European Union, following the recent approvals in the U.S. and Canada, offers patients across Europe a new and effective treatment to cure this serious disease," said Richard Gonzalez, chairman of the board and chief executive officer, AbbVie. "We are committed to working with local governments and healthcare systems to support broad access to VIEKIRAX + EXVIERA."
Full press release...
http://abbvie.mediaroom.com/2015-01-16-European-Commission-Grants-Marketing-Authorizations-for-AbbVies-VIEKIRAX-ombitasvir-paritaprevir-ritonavir-tablets-EXVIERA-dasabuvir-tablets-for-the-Treatment-of-Chronic-Hepatitis-C